Comparative prognostic value of systolic, diastolic, and pulse pressure

American Journal of Cardiology

Volumn 91, Issue 4, 2003, Pages 433-435

  Papademetriou, Vasilios ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; DEVELOPMENTAL STAGE; DIASTOLIC BLOOD PRESSURE; DIET; DISEASE COURSE; EDITORIAL; EXERCISE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MORTALITY; POOR GENERAL CONDITION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULSE PRESSURE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 0037441688     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03239-3     Document Type: Editorial

References (25)

1. Vasan R.S., Beiser A., Seshadri S., Larson M.G., Kannel W.B., D'Agostino R.B., Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men. JAMA. 287:2002;1003-1010.
2. Swales J.D. Hypertension in the political arena. (commentary) Hypertension. 35:2000;1179-1182.
3. Black H.R. Will better-tolerated antihypertensive agents improve blood pressure control? JNC VI revisted. Am J Hypertens. 12:1999;225S-230S.
4. Neaton J.D., Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Arch Int Med. 152:1992;56-64.
5. Franklin S.S., Gustin W. IV, Wong N.D., Larson M.G., Weber M.A., Kannel W.B., Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 96:1997;308-315.
6. Franklin S.S., Jacobs M.J., Wong N.D., L.', Italien G.J., Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives. Analysis based on National Health and Nutrition Examination Survey (NHANES III). Hypertension. 37:1998;869-874.
7. Staessen J., Amery A., Fagard R. Isolated systolic hypertension in the elderly. (editorial review) J Hypertens. 9:1990;393-405.
8. Franklin S.S. Aging and hypertension the assessment of blood pressure indices in predicting coronary heart disease . J Hypertens. 17:(suppl 5):1999;S29-S36.
9. Franklin S.S., Larson M.G., Khan S.A., Wong N.D., Leip E.P., Kannel W.B., Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 103:2001;1245-1249.
10. Kannel W.B., Gordon T., Schwartz M.J. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham Study. Am J Cardiol. 27:1971;335-345.
11. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 157:1997;2413-2445.
12. Izzo J.L. Jr, Levy D., Black H.R. Importance of systolic blood pressure in older Americans. Hypertension. 35:2000;1021-1024.
13. Chae C.U., Lloyd-Jones D.M. Isolated systolic hypertension in the elderly. Curr Treat Op Cardiovasc Med. 4:2002;87-93.
14. Rutan G.H., Kuller L.H., Neaton J.D., Wentworth D.N., McDonald R.H., Smith W.M. Mortality associated with diastolic hypertension and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation. 77:1988;504-514.
15. Black H.R., Yi J.-Y. A new classification scheme for hypertension based on relative and absolute risk with implications for treatment and reimbursement. Hypertension. 28:1996;719-724.
16. Alderman M.H. A new model of risk implications of increasing pulse pressure and systolic blood pressure on cardiovascular disease . J Hypertens. 17:(suppl 5):1999;S25-S28.
17. Hebert P.R., Moser M., Mayer J., Glynn R.J., Hennekens C.H. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 55:1993;578-581.
18. Glynn R.J., L'Italien G.J., Sesso H.D., Jackson E.A., Buring J.E. Development of predictive models for long-term cardiovascular risk associated with systolic and diastolic blood pressure. Hypertension. 39:2002;105-109.
19. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 265:1991;3255-3264.
20. Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P.-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 338:1991;1281-1285.
21. Wang J.G., Staessen J.A., Gong L., Liu L. Chinese trial on isolated systolic hypertension in the elderly. Arch Intern Med. 160:2000;211-220.
22. Birkenhager W.H., Staessen J.A. Treatment of diabetic patients with hypertension. Curr Hypertens Rep. 1:1999;225-231.
23. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., Ritz E., Atkins R.C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 345:2001;851-860.
24. Parving H.-H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 345:2001;870-878.
25. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol . Lancet. 359:2002;995-1003.